Tri-Isthmus Group

Tri-Isthmus Group is a clinical-stage biotechnology company focused on developing novel protein-based therapies for hard-to-treat cancers. The company's lead candidate, TIG-100, is a recombinant human protein derived from the C-terminal domain of Insulin-like growth factor binding protein 2 (IGFBP-2), designed to inhibit tumor growth and angiogenesis by modulating the tumor microenvironment. TIG-100 is currently being evaluated in clinical trials for patients with recurrent glioblastoma multiforme and other advanced solid tumors. The company aims to leverage its protein engineering expertise to address significant unmet needs in oncology through targeted microenvironment modulation.